AstraZeneca: Japan Approves BridgeBio Pharma-AstraZeneca Partnered Rare Heart Disease Drug
BridgeBio's acoramidis wins Japan's approval for ATTR-CM. Phase 3 data show a 42% reduction in key heart-related events. AstraZeneca's Alexion to market it. read more
Read full article »
CEO
Pascal Soriot
AstraZeneca is an England-based biopharmaceutical company that researches and develops prescription medicines for the treatment of cancer and renal diseases.
Read more